Recognition underscores CrossBridge Bio’s leadership in advancing next-generation dual-payload ADCs toward the clinic. HOUSTON, November 07, 2025--(BUSINESS WIRE)--CrossBridge Bio, a biopharmaceutical ...
HOUSTON, November 20, 2025--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer, ...
HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing of a $10 million ...
Crossbridge Bio Inc. has closed a $10 million seed financing to support its development of dual-payload antibody-drug conjugates (ADCs) for cancer. The company’s dual-payload ADC platform combines ...
Recognition underscores CrossBridge Bio’s leadership in advancing next-generation dual-payload ADCs toward the clinic. CrossBridge Bio, a biopharmaceutical company pioneering next-generation ...
CrossBridge Bio, a biopharmaceutical company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer more durable responses in patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback